MapLight Therapeutics
- Health & Biotech
- Redwood City, CA, US
- Founded 2021
- Public
- maplightrx.com
Clinical-stage biopharma developing oral therapies for central nervous system disorders such as schizophrenia and Alzheimer's disease psychosis.
$373MEquity raised in 2025–20262025 $373M · 2026 — · 1 equity round
$373MEquity raised, all time1 equity round sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 2 sources
Earlier rounds not yet sourced. MapLight Therapeutics was founded in 2021 and raised before 28 Jul 2025; only the rounds below are sourced so far, so its all-time equity total understates its history.
- Series DAmount$373MPost-money—✓ Confirmed
- Earlier rounds not yet sourced
Investors 8
- Forbion1
- Goldman Sachs1
- 5AM Ventures
- Avego BioScience Capital
- Blue Owl
- Novo Holdings
- Sanofi
- T. Rowe Price
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
OMass TherapeuticsHealth · $310M in 2025–2026Shared: Forbion, Sanofi +1Redwood MaterialsEnergy · $425M in 2025–2026Shared: Goldman Sachs, T. Rowe PriceTemporal TechnologiesEnterprise · $996M in 2025–2026Shared: Goldman Sachs, T. Rowe PriceClioEnterprise · $500M in 2025–2026Shared: Goldman Sachs, T. Rowe PriceAlphaSenseEnterprise · $350M in 2025–2026Shared: Goldman Sachs, Blue OwlSocureCyber · $156M in 2025–2026Shared: Goldman Sachs, T. Rowe Price
Also in the Redwood City hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. MapLight Therapeutics and its logo are trademarks of their owners, used here for identification only.
